Sana Biotechnology Inc. (SANA)

The total asset value of Sana Biotechnology Inc (SANA) stood at $ 501 Mln as on 31-Dec-24

The share price of Sana Biotechnology Inc (SANA) is $1.71 (NASDAQ) as of 29-Apr-2025 16:06 EDT. Sana Biotechnology Inc (SANA) has given a return of -38.83% in the last 3 years.

Sana Biotechnology Inc (SANA) has a market capitalisation of $ 398 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Sana Biotechnology Inc (SANA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sana Biotechnology Inc (SANA) and enter the required number of quantities and click on buy to purchase the shares of Sana Biotechnology Inc (SANA).

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. Address: 188 East Blaine Street, Seattle, WA, United States, 98102

The CEO & director of Dr. Steven D. Harr M.D.. is Sana Biotechnology Inc (SANA), and CFO & Sr. VP is Dr. Steven D. Harr M.D..

There is no promoter pledging in Sana Biotechnology Inc (SANA).

Some of the close peers are:

No, TTM profit after tax of Sana Biotechnology Inc (SANA) was $0 Mln.